BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting
—Two real-world studies demonstrate reductions in healthcare resource utilization in HAE patients who initiated or switched to ORLADEYO® from another prophylactic therapy—
Covered in this story
Call it yourself
No calls on $HAE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Haemonetics Corp →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.